Igor Francisco Chagas dos Santos

Dr. Igor Francisco Chagas dos Santos

orcid

Research Focus & Metrics

Representative Publications

View All Publications
19 March 2025 in AIDS Care
Verified
Journal Article
Closed access
ISIgor Francisco Chagas dos Santos
Igor Francisco Chagas dos Santos
AMAlexandre Sampaio Moura
Alexandre Sampaio Moura
MFMatheus Marchesotti Dutra Ferraz
Matheus Marchesotti Dutra Ferraz
CMCarla Moreira
Carla Moreira
PMPaula Meireles
Paula Meireles
MCMaria Das Gracas Braga Ceccato
Maria Das Gracas Braga Ceccato
Retrospective cohort aimed to analyze viral resistance mutations to integrase in people living with HIV/Aids (PLWHA) in Brazil. Patients receiving first-line therapy with a three-drug antiretroviral (ART) regimen containing dolutegravir (DTG), with HIV-1 genotypic resistance test available after starting treatment, were included. Data from three national databases related to antiretroviral dispensing, LT CD4+ cell count and HIV viral load (VL), and genotyping resistance testing were linked. Ideal adherence was defined as the proportion of days covered (PDC) ≥ 80%. Thirty (7.0%) of the 430 participants had resistance to DTG; five had high and 11 had moderate resistance levels. The N155H (n = 9) and E138K (n = 7) mutations were the most prevalent. DTG mutations were significantly more prevalent among males, whites, and those with HIV-VL count > 100,000 copies/mL, switching to alternative regimens or with resistance mutations to other classes of antiretroviral drugs (p < 0.05). Ideal ART adherence was observed in 52.8% of the participants and it was associated with DTG mutations (p < 0.001). This study described the resistance mutations to DTG in individuals starting treatment with this drug and the characteristics of such individuals. Understanding such a profile is crucial to regions where a DTG-containing regimen is the recommended first-line therapy.

1 September 2026 in Revista Ibero-Americana de Humanidades, Ciências e Educação
Verified
Journal Article
Open access
PDF file
CJCláudio Luiz Ferreira Júnior
Cláudio Luiz Ferreira Júnior
ASAline Silva de Assis Santos
Aline Silva de Assis Santos
KSKaren Karina Siqueira
Karen Karina Siqueira
TRThassio Ferraz Tavares Roque
Thassio Ferraz Tavares Roque
Cindy Ferreira LimaCindy Ferreira Lima
Cindy Ferreira Lima
ISIgor Francisco Chagas dos Santos
Igor Francisco Chagas dos Santos
A formação farmacêutica brasileira passou por sucessivas mudanças desde a institucionalização do ensino no período imperial. Este estudo analisa a evolução histórica do currículo de graduação em Farmácia no Brasil e suas contribuições para a consolidação do cuidado farmacêutico. Trata-se de revisão narrativa associada à análise documental de marcos educacionais e profissionais. Identificaram-se quatro movimentos: formação inicialmente orientada à preparação e ao conhecimento dos medicamentos; consolidação de currículos mínimos e habilitações no século XX; formação generalista instituída em 2002; e fortalecimento do Cuidado em Saúde nas Diretrizes Curriculares de 2017, em diálogo com a expansão das atribuições clínicas e com as Diretrizes Nacionais do Cuidado Farmacêutico no SUS. As mudanças favoreceram a incorporação de Farmácia Clínica, farmacoterapia, semiologia, comunicação, segurança do paciente, prescrição e acompanhamento farmacoterapêutico. Persistem, entretanto, heterogeneidades entre instituições. Conclui-se que a evolução curricular ampliou o objeto da formação, articulando o conhecimento técnico sobre medicamentos às necessidades das pessoas e do sistema de saúde.

18 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GSGustavo Gonçalves dos Santos
Gustavo Gonçalves dos Santos
GCGustavo da Silva Cândido
Gustavo da Silva Cândido
PPPatrícia Wottrich Parenti
Patrícia Wottrich Parenti
CSCélia Maria Pinheiro dos Santos
Célia Maria Pinheiro dos Santos
BMBrisa Cristina Rodrigues Cardoso Magalhães
Brisa Cristina Rodrigues Cardoso Magalhães
EMElizabeth Mollard
Elizabeth Mollard
Objective: To analyze the epidemiological profile of maternal mortality and its relationship with care indicators of the Restructuring and Redesign of the Maternal and Perinatal Care Network Project between 2010 and 2025. Methods: An observational, ecological, longitudinal, and analytical epidemiological study was conducted using aggregated secondary data from the panel of the Restructuring and Redesign of the Maternal and Perinatal Care Network Project, linked to the Brazilian Obstetric Observatory. 4,294 maternal deaths registered between 2010 and 2025 were analyzed. Descriptive analyses, calculation of proportion ratios, 95% confidence intervals, chi-square tests, odds ratios, and evaluation of the completeness of the information were performed. Results: A predominance of deaths was observed among white women (54.0%), mixed-race women (34.1%), and black women (9.5%). Direct maternal deaths accounted for 56.5% of cases, while 57.7% occurred during the postpartum period up to 42 days after delivery. Most deaths occurred in hospitals (92.4%) and among women who had received prior medical care (73.8%). Only 39.1% of cases were investigated by Maternal Mortality Committees. Black women were overrepresented in maternal deaths (OR=1.35; 95% CI: 1.16–1.57). It was estimated that 76.1% of deaths were potentially preventable. Conclusions: Maternal mortality in São Paulo remains marked by racial inequities, high preventability, and limitations in death surveillance. Strengthening the healthcare network, the quality of obstetric care, and information systems is fundamental to reducing maternal deaths.

14 November 2023 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
ISIgor Francisco Chagas dos Santos
Igor Francisco Chagas dos Santos
MFMatheus Marchesotti Dutra Ferraz
Matheus Marchesotti Dutra Ferraz
MCMaria Das Gracas Braga Ceccato
Maria Das Gracas Braga Ceccato
Introdução/Objetivo Em 2017, o dolutegravir (DTG) passou a ser recomendado com associação com lamivudina (3TC) e tenofovir (TDF) em dose fixa combinada como esquema inicial preferencial em pessoas vivendo com HIV (PVHIV) iniciando a terapia antirretroviral (TARV). Considerando a crescente utilização do DTG, avaliar adesão à TARV é fundamental para alcançar a supressão viral e minimizar o surgimento de falha virológica (FV). O presente estudo objetiva-se avaliar a adesão em indivíduos iniciando a TARV com DTG e apresentaram FV confirmada pelo teste de genotipagem. Métodos: Estudo de coorte retrospectiva utilizando informações obtidas pelo linkage entre bancos nacionais de dispensação de antirretrovirais e exames laboratoriais. Foram incluídos os indivíduos que iniciaram a TARV com esquemas contendo DTG e em algum momento do tratamento realizaram troca da TARV entre janeiro de 2017 e dezembro de 2019, no Brasil. Dados sociodemográficos, clínicos e relacionados ao tratamento foram obtidos com base nos registros de dados disponibilizados pelo Ministério da Saúde ao Grupo de pesquisa GEADIC. A adesão foi mensurada pela proporção de dias cobertos (PDC >80%) utilizando o cálculo CMA6 que permite mensurar o intervalo de dispensação de antirretrovirais pelo Sistema de Controle Logístico de Medicamentos (SICLOM) em diferentes intervalos. Os dados laboratoriais de CD4+ e carga viral (CV) foram obtidos pelo Sistema de Controle de Exames Laboratoriais (SISCEL) e a FV confirmada pelo teste de genotipagem no Sistema de Controle de Exames de Genotipagem (Sisgeno). Foi utilizado o pareamento probabilístico entre os três bancos e a biblioteca Python FuzzyWuzzy para a deduplicação dos dados. As análises foram realizadas utilizando o software SPSS v.22. Resultado: A amostra foi de 12.071 indivíduos, sendo 59,9% do sexo masculino, com idade ≥ a 40 anos (36,1%) da cor parda (38,0%) com média de 8 a 11 anos de estudo (22,7%), sem cônjuge (42,78%), CV-HIV detectável (34,0%), CD4+ > 500 cópias/mL (4,4%). Houve registro de FV em 0,8%. A adesão à TARV foi 68%. O grupo com registro com FV apresentou mais chance de ser não aderente (OR = 1,32), mas não houve significância estatística na associação (IC95%0,93-1,86; p = 0,111). Conclusão: Os resultados encontrados reforçam a necessidade de reconhecer precocemente a falha virológica e demonstram a importância de investigar os fatores associados a não adesão a TARV e ao surgimento de FV no início da TARV.

GSGabriel Souza-Silva
Gabriel Souza-Silva
ISIgor Francisco Chagas dos Santos
Igor Francisco Chagas dos Santos
Inês GomesInês Gomes
Inês Gomes
Manuel SimõesManuel Simões
Manuel Simões
MSMicheline Rosa Silveira
Micheline Rosa Silveira
AGAna I. Gomes
Ana I. Gomes
Pharmaceutical residues are increasingly detected in aquatic environments and are recognized as contaminants of emerging concern. This systematic literature review compiled and evaluated published concentrations of pharmaceutical residues in bottled water, tap water, and surface water in Portugal, applying risk quotient (RQ) and screening-level risk quotient (RQ_screen) approaches to evaluate potential human health risks and prioritize contaminants. Assessment based on the compiled literature data across age groups showed bottled and tap water posed low risk, while surface water presented the highest concern, with compounds spanning the full risk spectrum. Key contributors to potential human health risk included hormones (17-alpha-ethinylestradiol, 17-beta-estradiol, estrone), ramipril, betamethasone, citalopram, and amoxicillin. RQ_screen highlighted compounds relevant for ongoing monitoring even in treated waters, such as carbamazepine, diclofenac, salicylic acid, warfarin, fluoxetine, and erythromycin, due to their persistence and toxicological significance. Both RQ and RQ_screen indicated higher risk values for infants and children, reflecting lower body weight and higher water intake per unit mass, underscoring the need for age-specific evaluations. The RQ_screen method proved useful for contaminant prioritization, identifying substances relevant for monitoring despite low concentrations. Overall, this systematic review highlights pharmaceutical residues as an emerging public and environmental health concern in Portugal and emphasizes the importance of targeted monitoring and risk-based management within a One Health framework.

GSGabriel Souza-Silva
Gabriel Souza-Silva
MMMatheus Miranda
Matheus Miranda
ISIgor Francisco Chagas dos Santos
Igor Francisco Chagas dos Santos
LJLaíse Taciane Rodrigues Jardim
Laíse Taciane Rodrigues Jardim
CSCléssius R. Souza
Cléssius R. Souza
MSMicheline Rosa Silveira
Micheline Rosa Silveira
This study investigates the ecopharmacodynamics of antiretrovirals (ARVs) through an integrated cyclic model that correlates population consumption, environmental fate, and human re-exposure. In the assessed scenario, incomplete excretion introduces approximately 6.5 × 104 kg/year of unchanged drugs into sewage, led by darunavir (1.8 × 104 kg/year) and tenofovir disoproxil (1.0 × 104 kg/year). The ineffectiveness of conventional treatment plants (average removal of 59.8%) allows substantial fractions to reach water bodies or to partition strongly into residual sludge, reaching concentrations of 314 ng/g for zidovudine and 299 ng/g for lamivudine. In surface waters, elevated levels of nevirapine (81.1 µg/L) and lamivudine (30.2 µg/L) are observed, accompanied by significant sedimentary accumulation (zidovudine at 314 ng/g). Crucially, drinking water treatment systems prove unable to retain these compounds, culminating in the presence of abacavir (2.9 × 103 ng/L) and atazanavir (2.7 × 103 ng/L) in the drinking water supplied to the population. These data confirm that ARVs do not disappear after consumption but operate in an open anthropo-circulatory circuit, in which continuous water intake perpetually reinitiates human exposure, requiring advanced polishing technologies and One Health surveillance.